Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 plus nimotuzumab for KRAS G12D-mutant recurrent or metastatic pancreatic ductal adenocarcinoma after systemic therapy failure
ChiCTR2500098420Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of HRS-4642 and nimotuzumab, sponsored by West China Hospital of Sichuan University. Started Oct 2024; status: completed.
02
Drugs
HRS-4642nimotuzumab
Beyond the preview
Go deeper on ChiCTR2500098420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098420.